Entries by Business Wire

,

Merz Neurosciences to Present Key Clinical Data at the Annual Meeting of the American Academy of Neurology (AAN)

RALEIGH, N.C.–(BUSINESS WIRE)–Merz Neurosciences, a division of Merz North America (U.S. affiliate of the global Merz Pharma Group), announces that it will present top-line data from its Phase 3 PURE: Post-stroke Spasticity UppeR Limb Study to Investigate Efficacy and Safety of NT 201 clinical trial for incobotulinumtoxinA during the 67th Annual Meeting of the American […]

Epizyme Presents Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets

PHILADELPHIA–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the presentation of data on two epigenetic targets in its pioneering therapeutic pipeline. These data were presented this week at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Penn. Epizyme’s AACR 2015 posters […]

Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth

BOSTON–(BUSINESS WIRE)–Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and […]

,

Threat and Expense of Antitrust Litigation Grows in the Health Care Sector; ACE Report Identifies Due Diligence Practices to Help Mitigate Risk

PHILADELPHIA–(BUSINESS WIRE)–ACE Group today released a new white paper examining the increased risk of antitrust litigation in the health care market. The paper analyzes the recent growth in health care industry transactions and the corresponding rise in antitrust regulation and government enforcement. It also outlines key due diligence practices that health care market participants should […]

Baxter International’s Bleeding Disorder Drug Delivers 100 % Percent Success Rate in Late-Stage Study

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX) today presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1 The data were presented as an Abstract of […]

,

Merck Announces Submission of Supplemental Biologics License Application to U.S. FDA for KEYTRUDA in Advanced Non-Small Cell Lung Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer (NSCLC). KEYTRUDA previously received Breakthrough Therapy […]

KEYTRUDA, Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy…

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA® (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, […]

Early Findings with KEYTRUDA, Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an […]

,

Peloton Therapeutics Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting

DALLAS & PHILADELPHIA–(BUSINESS WIRE)–Peloton Therapeutics Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities, presented preclinical data on its lead investigational candidate, PT2385, at the American Association for Cancer Research Annual Meeting in Philadelphia, PA. PT2385 is the first clinical stage antagonist of hypoxia inducible […]

Epizyme Announces Closing of Common Stock Offering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme. The underwriters purchased 701,448 shares from Epizyme at […]